|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1987-7-9
|
|
pubmed:abstractText |
A series of 6,14-dideoxynaltrexones that contain different electrophiles in the 6-position were synthesized and evaluated for nonequilibrium opioid antagonist activity in the guinea pig ileum and mouse vas deferens preparations. Members 3-5 of the series possessed irreversible antagonist activity profiles similar to those previously reported for the 14-hydroxy analogues. In contrast, the 14-deoxy-beta-funaltrexamine (14-deoxy-beta-FNA) analogue (6) exhibited a profile of irreversible antagonist activity that differed from that of beta-FNA. It was concluded that the 14-hydroxy group is not essential for irreversible blockage when the electrophile is capable of reacting with a broad spectrum of nucleophiles. However, with a highly selective electrophile such as the fumarate group, the 14-hydroxy function appears to play a role in aligning the molecule to optimize attack by a receptor-based nucleophile.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1040-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:3035177-Animals,
pubmed-meshheading:3035177-Cyclazocine,
pubmed-meshheading:3035177-Dose-Response Relationship, Drug,
pubmed-meshheading:3035177-Enkephalin, Leucine,
pubmed-meshheading:3035177-Enkephalin, Leucine-2-Alanine,
pubmed-meshheading:3035177-Ethylketocyclazocine,
pubmed-meshheading:3035177-Guinea Pigs,
pubmed-meshheading:3035177-Mice,
pubmed-meshheading:3035177-Naltrexone,
pubmed-meshheading:3035177-Narcotic Antagonists,
pubmed-meshheading:3035177-Receptors, Opioid,
pubmed-meshheading:3035177-Structure-Activity Relationship
|
|
pubmed:year |
1987
|
|
pubmed:articleTitle |
Nonequilibrium opioid antagonist activity of 6,14-dideoxynaltrexone derivatives.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
